近期急性心力衰竭患者接受TAVR与SAVR的结局
基于FinnValve全国注册研究,评估主动脉瓣狭窄患者在TAVR或SAVR前60天内发生急性心力衰竭(AHF)对预后的影响。SAVR队列中近期AHF患病率为11.4%,TAVR队列为11.3%。近期AHF与SAVR和TAVR术后死亡率和并发症风险增加相关。
要点
- SAVR术前近期AHF与30天和5年生存率降低独立相关。
- TAVR术前近期AHF与5年生存率显著降低相关,30天生存率有降低趋势。
- 近期AHF增加术后急性肾损伤、 prolonged hospital stay和复合终点风险。
核心结论
- 近期急性心力衰竭与SAVR和TAVR术后死亡率和并发症风险增加相关。
- 主动脉瓣狭窄患者应在出现临床明显心力衰竭前转诊接受侵入性治疗。
研究设计与样本
- 基于FinnValve全国注册研究的分析,纳入因主动脉瓣狭窄行初次TAVR或SAVR并置入生物瓣的患者。
- 评估TAVR或SAVR前60天内发生急性心力衰竭(AHF)患者的结局。
主要发现
- SAVR队列中近期AHF患病率为11.4%(484/4241),TAVR队列为11.3%(210/1855)。
- SAVR队列中,AHF与较低的30天生存率相关(91.3% vs 97.0%;调整OR 1.801,95%CI 1.125-2.882)。
- SAVR队列中,AHF与较低的5年生存率相关(64.0% vs 81.2%;调整HR 1.482,95%CI 1.207-1.821)。
- SAVR合并AHF患者的大出血、机械循环支持需求、急性肾损伤、延长住院和复合终点风险更高。
- TAVR队列中,AHF患者30天生存率有降低趋势(粗率95.2% vs 97.9%;调整OR 2.028,95%CI 0.908-4.529),5年生存率显著降低(粗率45.3% vs 58.5%;调整HR 1.530,95%CI 1.185-1.976)。
临床怎么用
- 对主动脉瓣狭窄患者应尽早评估并转诊,避免等待至临床明显心力衰竭发生。
- 术前近期AHF患者术后需加强监测和并发症防治。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with severe aortic stenosis and heart failure have poor prognosis, and their outcomes may be suboptimal even after transcatheter (TAVR) and surgical aortic valve replacement (SAVR). METHODS: This is an analysis of the nationwide FinnValve registry, which included patients who underwent primary TAVR or SAVR with a bioprothesis for aortic stenosis. We evaluated the outcome of patients with acute heart failure (AHF) within 60 days prior to TAVR or SAVR. RESULTS: The prevalence of recent AHF was 11.4% (484 of 4241 patients) in the SAVR cohort and 11.3% (210 of 1855 patients) in the TAVR cohort. In the SAVR cohort, AHF was associated with lower 30-day survival (91.3% vs 97.0%; adjusted odds ratio 1.801, 95% confidence interval [CI] 1.125-2.882) and 5-year survival (64.0% vs 81.2%; adjusted hazard ratio 1.482, 95% CI 1.207-1.821). SAVR patients with AHF had higher risk of major bleeding, need of mechanical circulatory support, acute kidney injury, prolonged hospital stay, and composite end-point (30-day mortality, stroke and/or acute kidney injury). Patients with AHF had a trend toward lower 30-day survival (crude rates 95.2% vs 97.9%; adjusted odds ratio 2.028, 95% CI 0.908-4.529) as well as significantly lower 5-year survival (crude rates 45.3% vs 58.5%; adjusted hazard ratio 1.530, 95% CI 1.185-1.976) also after TAVR. AHF increased the risk of acute kidney injury, prolonged hospital stay, and composite end-point after TAVR. CONCLUSIONS: Recent AHF is associated with increased risk of mortality and morbidity after SAVR and TAVR. These findings suggest that aortic stenosis patients should be referred for invasive treatment before the development of clinically evident heart failure.
引用
- Jalava MP, Laakso T, Virtanen M, et al. Transcatheter and Surgical Aortic Valve Replacement in Patients With Recent Acute Heart Failure. Ann Thorac Surg. 2019. PMID: 31288017. doi:10.1016/j.athoracsur.2019.05.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。